Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBellerophon Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 1 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 1 | -$1.50 | -$1.50 | -$1.50 |
| Q4 2024 | 1 | -$0.85 | -$0.85 | -$0.85 |
| Q1 2025 | 1 | -$1.10 | -$1.10 | -$1.10 |
| Q2 2025 | 1 | -$1.05 | -$1.05 | -$1.05 |
| Q3 2025 | 1 | -$1.02 | -$1.02 | -$1.02 |
| Q4 2025 | 1 | -$0.72 | -$0.72 | -$0.72 |
| Q1 2026 | 1 | -$0.83 | -$0.83 | -$0.83 |
| Q2 2026 | 1 | -$0.91 | -$0.91 | -$0.91 |
| Q3 2026 | 1 | -$0.71 | -$0.71 | -$0.71 |
| Q4 2026 | 1 | -$0.62 | -$0.62 | -$0.62 |
| Q1 2027 | 1 | -$0.61 | -$0.61 | -$0.61 |
| Q2 2027 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q3 2027 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q4 2027 | 1 | -$0.61 | -$0.61 | -$0.61 |
| Q1 2028 | 1 | -$0.59 | -$0.59 | -$0.59 |
| Q2 2028 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q3 2028 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q4 2028 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q1 2029 | 1 | -$0.33 | -$0.33 | -$0.33 |
| Q2 2029 | 1 | -$0.33 | -$0.33 | -$0.33 |
Bellerophon Therapeutics, Inc. Earnings Date And Information
Bellerophon Therapeutics, Inc. last posted its earnings results on Tuesday, November 14th, 2023. The company reported $-0.16 earnings per share for the quarter, topping analysts' consensus estimates of $-0.44 by $0.28. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Bellerophon Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.08 diluted earnings per share) and currently has a price-to-earnings ratio of -0.02. Bellerophon Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 19th, 2024 based on prior year's report dates.
Bellerophon Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2023 | Q3 2023 | -$0.44 | -$0.16 | 0.28 | $0 | $0 |
| 08/14/2023 | Q2 2023 | -$0.42 | -$0.42 | 0 | $0 | |
| 05/15/2023 | Q1 2023 | -$0.48 | $0.27 | 0.75 | $5.64 M | |
| 03/31/2023 | Q4 2022 | -$0.48 | -$0.78 | -0.3 | $0 | |
| 11/14/2022 | Q3 2022 | -$0.59 | -$0.53 | 0.06 | $0 | |
| 08/15/2022 | Q2 2022 | -$0.61 | -$0.43 | 0.18 | $0 | |
| 05/11/2022 | Q1 2022 | -$0.55 | -$0.59 | -0.04 | $0 | |
| 03/31/2022 | Q4 2021 | -$0.60 | -$0.45 | 0.15 | $0 | |
| 11/15/2021 | Q3 2021 | -$0.63 | -$0.49 | 0.14 | $0 | |
| 08/05/2021 | Q2 2021 | -$0.66 | -$0.36 | 0.3 | $0 | |
| 05/11/2021 | Q1 2021 | -$0.71 | -$0.58 | 0.13 | $0 | |
| 03/11/2021 | Q4 2020 | -$0.90 | -$0.84 | 0.06 | $0 | |
| 11/05/2020 | Q3 2020 | -$0.82 | -$0.84 | -0.02 | $0 | |
| 08/05/2020 | Q2 2020 | -$0.68 | -$0.51 | 0.17 | $0 | |
| 05/11/2020 | Q1 2020 | -$1.02 | -$1.08 | -0.06 | $0 | |
| 04/06/2020 | Q4 2019 | -$0.89 | $0 | |||
| 11/06/2019 | Q3 2019 | -$1.20 | -$0.94 | 0.26 | $0 | |
| 08/08/2019 | Q2 2019 | -$1.05 | -$0.90 | 0.15 | $0 | |
| 05/09/2019 | Q1 2019 | -$0.18 | $0 | |||
| 03/14/2019 | Q4 2018 | -$1.80 | -$0.21 | 1.59 | $0 |
Bellerophon Therapeutics, Inc. Earnings: FAQ's
When is Bellerophon Therapeutics, Inc.'s earnings date?
Bellerophon Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 19th, 2024 based off last year's report dates.
Did Bellerophon Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Bellerophon Therapeutics, Inc. (:BLPH) reported $-0.16 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.44 by $0.28.
How can I listen to Bellerophon Therapeutics, Inc.'s earnings conference
call?
The conference call for Bellerophon Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Bellerophon Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Bellerophon Therapeutics, Inc.'s latest earnings report can be read online.
How much profit does Bellerophon Therapeutics, Inc. generate each year?
Bellerophon Therapeutics, Inc. (:BLPH) has a recorded net income of $0. Bellerophon Therapeutics, Inc. has generated $-2.08 earnings per share over the last four quarters.
What is Bellerophon Therapeutics, Inc.'s price-to-earnings ratio?
Bellerophon Therapeutics, Inc. (:BLPH) has a price-to-earnings ratio of -0.02 and price/earnings-to-growth ratio is -0.